RS61607B1 - Kompozicije i postupci za nanočestične liofilne oblike - Google Patents

Kompozicije i postupci za nanočestične liofilne oblike

Info

Publication number
RS61607B1
RS61607B1 RS20210355A RSP20210355A RS61607B1 RS 61607 B1 RS61607 B1 RS 61607B1 RS 20210355 A RS20210355 A RS 20210355A RS P20210355 A RSP20210355 A RS P20210355A RS 61607 B1 RS61607 B1 RS 61607B1
Authority
RS
Serbia
Prior art keywords
cholesteryl
compound
cyclodextrin
hydroxyalkyl
composition
Prior art date
Application number
RS20210355A
Other languages
English (en)
Serbian (sr)
Inventor
Wenbin Ying
Roger Adami
Yuwei Wang
Haiqing Yin
Liping Wang
Dong Liu
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of RS61607B1 publication Critical patent/RS61607B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20210355A 2015-07-22 2016-07-22 Kompozicije i postupci za nanočestične liofilne oblike RS61607B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
EP16828602.9A EP3324932B1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Publications (1)

Publication Number Publication Date
RS61607B1 true RS61607B1 (sr) 2021-04-29

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210355A RS61607B1 (sr) 2015-07-22 2016-07-22 Kompozicije i postupci za nanočestične liofilne oblike

Country Status (23)

Country Link
US (3) US10300018B2 (cg-RX-API-DMAC7.html)
EP (1) EP3324932B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875373B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716928B1 (cg-RX-API-DMAC7.html)
CN (2) CN108024957B (cg-RX-API-DMAC7.html)
AU (1) AU2016297153B2 (cg-RX-API-DMAC7.html)
CA (1) CA2992849C (cg-RX-API-DMAC7.html)
CY (1) CY1123984T1 (cg-RX-API-DMAC7.html)
DK (1) DK3324932T3 (cg-RX-API-DMAC7.html)
EA (1) EA035761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2862191T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210523T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053990T2 (cg-RX-API-DMAC7.html)
IL (2) IL288342B2 (cg-RX-API-DMAC7.html)
LT (1) LT3324932T (cg-RX-API-DMAC7.html)
MX (1) MX373982B (cg-RX-API-DMAC7.html)
PL (1) PL3324932T3 (cg-RX-API-DMAC7.html)
PT (1) PT3324932T (cg-RX-API-DMAC7.html)
RS (1) RS61607B1 (cg-RX-API-DMAC7.html)
SI (1) SI3324932T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100196T1 (cg-RX-API-DMAC7.html)
TW (1) TWI732773B (cg-RX-API-DMAC7.html)
WO (1) WO2017015552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61607B1 (sr) * 2015-07-22 2021-04-29 Nitto Denko Corp Kompozicije i postupci za nanočestične liofilne oblike
US20210069121A1 (en) 2017-12-12 2021-03-11 Lead Biotherapeutics Ltd Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
IL281135B2 (en) 2018-09-28 2024-12-01 Nutcracker Therapeutics Inc Tertiary amino lipidated cationic peptides for nucleic acid delivery
WO2020102668A1 (en) * 2018-11-16 2020-05-22 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
JP7597334B2 (ja) * 2019-09-26 2024-12-10 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
CA3173554A1 (en) * 2020-02-28 2021-09-02 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
US20220023204A1 (en) * 2020-04-20 2022-01-27 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
CA3191874A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
TW202228652A (zh) 2020-10-02 2022-08-01 國立大學法人北海道大學 脂質奈米粒子
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
WO2024151942A2 (en) 2023-01-13 2024-07-18 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
WO2025015189A1 (en) * 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
EP1534340B1 (en) 2002-09-06 2011-11-16 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
ES2350485T3 (es) 2003-06-04 2011-01-24 Georgetown University Método para mejorar la estabilidad y la duración de conservación de complejos de liposomas.
CA2584583A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
CA2587337A1 (en) 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
JP5334170B2 (ja) * 2007-02-09 2013-11-06 国立大学法人 奈良先端科学技術大学院大学 Ｃ７０含有リポソームおよびその製造方法、並びにその利用
ES2721898T3 (es) * 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
DK3336082T3 (da) * 2011-06-08 2020-04-27 Translate Bio Inc Spaltelige lipider
US9011903B2 (en) * 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
RU2648753C2 (ru) 2011-10-21 2018-03-28 Селатор Фармасьютикалз Инк. Лиофилизированные липосомы
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
SI2773326T1 (sl) 2011-11-04 2019-04-30 Nitto Denko Corporation Metoda za sterilno proizvodnjo delcev lipidno-nukleinske kisline
EP2723323B1 (en) 2012-03-28 2015-09-23 Discovery Laboratories, Inc. Lyophilization of synthetic liposomal pulmonary surfactant
ES2858523T3 (es) * 2012-03-29 2021-09-30 Translate Bio Inc Nanopartículas neutras derivadas de lípidos
TWI654997B (zh) 2012-06-08 2019-04-01 日商日東電工股份有限公司 用於治療劑輸送配方之脂質
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
RS61607B1 (sr) * 2015-07-22 2021-04-29 Nitto Denko Corp Kompozicije i postupci za nanočestične liofilne oblike

Also Published As

Publication number Publication date
JP2021119161A (ja) 2021-08-12
US12311055B2 (en) 2025-05-27
CA2992849A1 (en) 2017-01-26
AU2016297153A1 (en) 2018-03-01
CN108024957B (zh) 2021-08-24
MX373982B (es) 2020-07-15
EP3324932A1 (en) 2018-05-30
IL288342B2 (en) 2024-02-01
CN113679689A (zh) 2021-11-23
SMT202100196T1 (it) 2021-05-07
IL257029A (en) 2018-03-29
IL257029B (en) 2021-12-01
US20170020819A1 (en) 2017-01-26
LT3324932T (lt) 2021-04-26
PT3324932T (pt) 2021-04-06
TWI732773B (zh) 2021-07-11
EA201890367A1 (ru) 2018-06-29
ES2862191T3 (es) 2021-10-07
CY1123984T1 (el) 2022-05-27
KR20180030698A (ko) 2018-03-23
JP2018521083A (ja) 2018-08-02
HUE053990T2 (hu) 2021-08-30
EP3324932B1 (en) 2021-03-10
AU2016297153B2 (en) 2021-02-25
DK3324932T3 (da) 2021-04-06
HRP20210523T1 (hr) 2021-05-14
US11737982B2 (en) 2023-08-29
US20190231695A1 (en) 2019-08-01
IL288342A (en) 2022-01-01
WO2017015552A1 (en) 2017-01-26
JP6875373B2 (ja) 2021-05-26
EA035761B1 (ru) 2020-08-06
US20240000710A1 (en) 2024-01-04
IL288342B1 (en) 2023-10-01
JP7268079B2 (ja) 2023-05-02
TW201717914A (zh) 2017-06-01
EP3324932A4 (en) 2019-03-06
CA2992849C (en) 2023-06-13
US10300018B2 (en) 2019-05-28
PL3324932T3 (pl) 2021-07-05
CN113679689B (zh) 2023-09-01
CN108024957A (zh) 2018-05-11
SI3324932T1 (sl) 2021-07-30
MX2018000891A (es) 2018-06-11
KR102716928B1 (ko) 2024-10-11
BR112018001178A2 (pt) 2018-09-11

Similar Documents

Publication Publication Date Title
JP7268079B2 (ja) ナノ粒子凍結乾燥形態のための組成物および方法
TWI355946B (en) Proliposomal and liposomal compositions of poorly
EP2664324B1 (en) Nanocapsules with a polymer shell
Vangala et al. Combating glioblastoma by codelivering the small-molecule inhibitor of STAT3 and STAT3siRNA with α5β1 integrin receptor-selective liposomes
CN104622817A (zh) 一种蛋白-聚合物复合纳米载体及其制备方法
ES2377352T3 (es) Nuevas composiciones a base de taxoides
JP2023168587A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
AU2017259576B2 (en) Polymerized drug-containing pharmaceutical composition
JP2023093769A (ja) Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法
BR112018001178B1 (pt) Composição, processo de produção de liófilo sólido, liófilo sólido, processo de preparação de um medicamento, medicamento e processo de preparação de um medicamento de ácido nucleico
EP3395370B1 (en) Liposome and liposome composition
JP3283543B2 (ja) 脂溶性肝疾患治療薬とｐｖｌａとの包接化合物
EA005308B1 (ru) Препараты эстрамустинфосфата для парентерального применения